Table 4. Safety analysis.
| Adverse effects | SBP < 100 mmHg (n = 47) | SBP ≥ 100 mmHg (n = 70) | P-value |
| Permanent discontinuation due to hypotension | 3 (6.4%) | 4 (5.7%) | 1.000 |
| Hyperkalemia | 0 | 0 | – |
| Renal impairment | 3 (6.4%) | 0 | 0.062 |
| Angioedema | 0 | 0 | – |
| Stroke | 0 | 2 (2.9%) | 0.515 |